Molecular Determinants of Head and Neck Cancer

  • Barbara Burtness
  • Erica A. Golemis

Part of the Current Cancer Research book series (CUCR)

Table of contents

  1. Front Matter
    Pages i-vi
  2. Barbara Burtness, Erica A. Golemis
    Pages 1-5
  3. Anna Kiseleva, Tim N. Beck, Ilya G. Serebriiskii, Hanqing Liu, Barbara Burtness, Erica A. Golemis
    Pages 7-61
  4. John Kaczmar, Tim N. Beck
    Pages 63-88
  5. Alexander Y. Deneka, Jason D. Howard, Christine H. Chung
    Pages 117-154
  6. Elizabeth Cedars, Daniel E. Johnson, Jennifer R. Grandis
    Pages 155-184
  7. Adrian D. Schubert, Fernando T. Zamuner, Nyall R. London Jr, Alex Zhavoronkov, Ranee Mehra, Mohammad O. Hoque et al.
    Pages 229-248
  8. Janaki Parameswaran, Barbara Burtness
    Pages 249-274
  9. Tomoaki Sasaki, Natalia Issaeva, Wendell G. Yarbrough, Karen S. Anderson
    Pages 275-292
  10. Farhoud Faraji, Adrian D. Schubert, Luciane T. Kagohara, Marietta Tan, Yanxun Xu, Munfarid Zaidi et al.
    Pages 293-325
  11. Suraj Peri, Andrew J. Andrews, Aarti Bhatia, Ranee Mehra
    Pages 327-352
  12. Paul E. Clavijo, Clint T. Allen, Nicole C. Schmitt, Carter Van Waes
    Pages 353-364
  13. Jennifer Moy, Robert L. Ferris
    Pages 365-396
  14. Annette M. Lim, Quynh-Thu Le, Danny Rischin
    Pages 397-438
  15. Lindsay Wilde, Jennifer Johnson, Athanassios Argiris
    Pages 439-467
  16. Nassim Khosravi, Heath Skinner, John Heymach
    Pages 469-490
  17. Alexander Y. Deneka, Jeffrey C. Liu, Camille C. R. Ragin
    Pages 545-583
  18. Christien A. Kluwe, Anthony J. Cmelak
    Pages 585-615
  19. Back Matter
    Pages 617-629

About this book


Squamous cell cancers of the head and neck (SCCHN), also known as head and neck cancers (HNC) encompass malignancies of the oral cavity, larynx, nasopharynx and pharynx, and are diagnosed in over 500,000 patients worldwide each year, accounting for 5% of all malignancies. It is estimated that approximately 50,000 patients develop head and neck cancer annually in the United States, of whom approximately 50% succumb to this cancer. For most cases of SCCHN, treatment is multimodal, often combining surgery or irradiation with chemotherapy; even successfully treated patients frequently experience durable and severe side effects.  Improving cure rates and reducing chronic morbidity are urgent clinical needs for head and neck cancer.  However, in contrast to cancer types such as breast or prostate that have been much studied and have well-defined biology, until recently, relatively few researchers investigated the molecular basis of HNC, making it difficult to design targeted treatments with better efficacy and less debilitating side effects. 

This volume will provide an overview of the factors contributing to disease pathogenesis, including the recognition of discrete molecular subtypes with distinct etiology, prognosis, and treatment response.  This volume will familiarize the reader with the critical signaling pathways and oncogenic drivers for HNC. It will outline the differences between HPV-positive and HPV-negative disease, and how these differences affect treatment choice and outcome.  The book will emphasize developments in the past five years, including the growing understanding of the genomic and epigenomic features of the disease based on analysis of next generation sequencing (NGS) data, and timely topics such as the analysis of HNC stem cell populations, non-coding mRNAs, and inflammatory response.  It will address exciting new therapeutic approaches such as the use of immunotherapies to treat HNC patients.  Overall, the book will provide the reader with current understanding of the biology and treatment of the disease, and describe timely questions that will guide future research aimed at controlling and curing this disease.


DNA repair Genomics Head and neck cancer Human Papillomavirus Hypoxia Molecular determinants

Editors and affiliations

  • Barbara Burtness
    • 1
  • Erica A. Golemis
    • 2
  1. 1.Department of Internal MedicineYale University School of MedicineNew HavenUSA
  2. 2.Molecular Therapeutics ProgramFox Chase Cancer CenterPhiladelphiaUSA

Bibliographic information

  • DOI
  • Copyright Information Springer International Publishing AG, part of Springer Nature 2018
  • Publisher Name Humana Press, Cham
  • eBook Packages Medicine Medicine (R0)
  • Print ISBN 978-3-319-78761-9
  • Online ISBN 978-3-319-78762-6
  • Series Print ISSN 2199-2584
  • Series Online ISSN 2199-2592
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods